VVOS Vivos Therapeutics, Inc.
$0.06
Vivos Therapeutics, Inc. (VVOS) Earnings News
Earnings press releases, previews and reviews for Vivos Therapeutics, Inc. (VVOS), newest first. Our most recent is review: Vivos Therapeutics Beats Estimates, but a One-Time Credit and a $247,000 Cash Balance Overshadow the Quarter.
Monday
November 16, 2026
9:41 PM ET
Vivos Therapeutics Beats Estimates, but a One-Time Credit and a $247,000 Cash Balance Overshadow the Quarter
Earnings Whispers · Review
Monday
November 16, 2026
6:31 PM ET
Vivos Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Update
Monday
October 19, 2026
5:01 PM ET
Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel
Thursday
October 15, 2026
8:45 AM ET
Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test
Friday
August 14, 2026
4:28 PM ET
Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update
Friday
August 14, 2026
8:45 AM ET
Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call